Palvella Therapeutics, Inc. (PVLA) Research

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.

Market snapshot

Symbol
PVLA
Price
$113.1
Day change
+0.42%
Market cap
$1.3B
P/E ratio
-30.02x
52-week range
20.35-151.18
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$225

Peer companies

  • Arbutus Biopharma Corporation (ABUS)
  • EyePoint Pharmaceuticals, Inc. (EYPT)
  • GH Research PLC (GHRS)
  • Kura Oncology, Inc. (KURA)
  • Nanobiotix S.A. (NBTX)
  • ProKidney Corp. (PROK)
  • Rezolute, Inc. (RZLT)
  • ARS Pharmaceuticals, Inc. (SPRY)

Recent insider activity

  • Korenberg Matthew E — M-Exempt (1000 shares) on 2026-06-12
  • Korenberg Matthew E — M-Exempt (1000 shares) on 2026-06-12
  • KIRITSY CHRISTOPHER P — A-Award (3000 shares) on 2026-06-10
  • JENKINS GEORGE M — A-Award (3000 shares) on 2026-06-10
  • HERON ELAINE J — A-Award (3000 shares) on 2026-06-10

Open Palvella Therapeutics, Inc. (PVLA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.